Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis

Cells. 2021 Aug 22;10(8):2164. doi: 10.3390/cells10082164.

Abstract

Multiple sclerosis and Alzheimer's disease are two complex neurodegenerative diseases involving the immune system. So far, available treatments provide at best mild improvements to patients' conditions. For decades now, a new set of molecules have been used to modulate and regulate the innate immunity in these pathologies. Most studies have been carried out in rodents and some of them have reported tremendous beneficial effects on the disease course. The modulation of innate immune cells is of great interest since it provides new hope for patients. In this review, we will briefly overview the therapeutic potential of some molecules and receptors in multiple sclerosis and Alzheimer's disease and how they could be used to exploit new therapeutic avenues.

Keywords: MPL; NOD2; Toll-like receptor; amyloid; innate immunity; mCSF; microglia; monocytes; muramyl-dipeptide.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Humans
  • Immunity, Innate / physiology
  • Multiple Sclerosis / metabolism*
  • Receptors, Immunologic / metabolism*

Substances

  • Receptors, Immunologic

Grants and funding